<strong>Advances in Parkinson’s Disease-Causing Gene Parkin</strong>

Abstract

Abstract:In the global neurodegenerative diseases，the incidence of Parkinson is second only to Alzheimer’s disease. Parkin is one of the gene which associated with Parkinson’s disease. Since the hypothesis that Parkin is associated with the Parkinson’s disease was confirmed by Japannese scholar，the researches about it were developed rapidly. The basic structure，physiological function，the protein substrates and related genes，accompanied their pathogenic mechanisms of Parkin have been reported in numerous literature. This paper describes the structure and protein of Parkin，reviews Parkin and its ubiquitin-protein enzyme system in detail，describes the relationship between Parkin and that the relevant reactants and mitochondria，and proposes ideas for their development prospects.

Key words:Parkin,Parkinson&,rsquo,s disease,Substrates,Gene mutation,Ubiquitination

CLC Number:

R964

JIANG Yi-na, CHEN Nai-hong.Advances in Parkinson’s Disease-Causing Gene Parkin[J]. ACTA NEUROPHARMACOLOGICA, 2015, 5(3): 36-45.

References

[1] Dorsey E R, Constantinescu R, Thompson J P, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030[J]. Neurology, 2007, 68(5): 384–386.

[2] 王雪晶, 郭纪锋, 江泓, 等. 帕金森病相关蛋白Parkin 与PINK1的相互作用研究[J]. 生物化学和生物物理进展, 2010, 37(9): 983-987.

[3] Rainer von Coelln, Valina L Dawson, Ted M Dawson. Parkin-associated Parkinson’s disease[J]. Cell Tissue Res, 2004, 318: 175-184.

[4] Tohru Kitada, Shuichi Asakawa, Hattori N, et al. Mutations in the Parkin gene cause autosomal recessive juvenile Parkinsonism[J]. Nature, 1998, 392(6676): 605-608.

[5] Ruth Lovering, Isabel M Hanson, Katherine Borden, et al. Identification and preliminary characterization of aprotein motif related to the zinc finger[J]. Proc Natl Acad, 1993, 90(6): 2112-2116.

[6] Ignacio Marin, Alberto Ferrus. Comparative genomics of the RBR family, including the Parkinson's disease-related gene Parkin and the genes of the ariadne subfamily[J]. Mol Biol Evol, 2002, 19(12): 2039-2050.

[7] Carolyn A, Rankin Ambrish Roy, Yang Zhang, et al. Parkin, a top level manager in the cell’s sanitation department[J]. J Open Biochemistry, 2011, 5: 9-26.

[8] Iris H Henn, Johanna M Gostner, Peter Lackner, et al. Pathogenic mutations inactivate Parkin by distinct mechanisms [J]. Neurochem, 2005, 92(1): 114-122.

[9] Su Jin Ham, Soo Young Lee, Saera Song, et al. Interaction between RING1 (R1) and the Ubiquitin-like (UBL) Domains Is Critical for the Regulation of Parkin Activity[J]. J Biol Chem, 2016, 291(4): 1803-1816.

[10] Ventzislava A Hristova, Steven A Beasley, R Jane Rylett, et al. Identification of a novel Zn2+-binding domain in the autosomal recessive juvenile Parkinson-related E3 ligase Parkin[J]. Bio Chem, 2009, 284(22): 14978-14986.

[11] Beasley S A, Hristova V A, Shaw G S. Structure of the Parkinin-between-ring domain provides insights for E3-ligase dysfunction in autosomal recessive Parkinson's disease[J], Proc Natl Acad, 2007, 104(9): 3095-3100.

[12] Cecile M Pickart, Michael J Eddins. Ubiquitin: structure, functions, mechanisms[J]. Biochimica Et Biophysica Acta, 2004, 1695(1-3): 55-72.

[13] Kreider-Mueller A, Quinlivan PJ, Rauch M, et al. Synthesis, structure and reactivity of [Tm(Bu(t)]ZnH, a monomeric terminal zinc hydride compound in a sulfur-rich coordination environment: access to a heterobimetallic compound[J]. Chem Commun (Camb), 2016, 52(11): 2358-2361.

[14] Jan-Michael Peters, Werner W Franke, Jurgen A Kleinschmidt. Distinct 19S and 20S subcomplexes of the 26S proteasome and their distribution in the nucleus and the cytoplasm[J]. J Biol Chem, 1994, 269(10): 7709-7718.

[15] Jean-Francois Trempe, Veronique Sauvé, Karl Grenier, et al. Structure of Parkin reveals mechanisms for ubiquitin ligase activation[J]. Science, 2013, 340(6139): 1451-1455.

[16] Tu Ya-qin, Chen Cai, Pan Jun-ru, et al. The ubiquitin proteasome pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis[J]. Int J Clin Exp Pathol, 2012, 5(8): 726-738.

[17] Namrata Rastogi, Durga Prasad Mishra. Therapeutic targeting of cancer cell cycle using proteasome inhibitors[J]. Cell Div, 2012, 7(1): 26.

[18] Khullar V, Cardozo L. The urethra (UPP, MUPP, instability, LPP)[J]. Eur Urol, 1998, 34 (Suppl 1): 20-22.

[19] Joao H Duarte. Autoimmunity: Antigen presentation by B cells contributes to murine lupus[J]. Nat Rev Rheumatol, 2015: 1759-4790.

[20] Kenny K K Chung, Valina L Dawson, Ted M Dawson. The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders[J]. Trends Neurosci, 2001, 24(Suppl 11): 7-14.

[21] Zhang Yao-Quan, Feng Bing, Yuan Fa-Huan. Effect of chronic renal failure medium on the ubiquitin proteasome pathway of arterial muscle cells[J]. Mol Med Rep, 2013, 7(3): 1021-1025.

[22] Yamasaki L, Pagano M. Cell cycle, proteolysis and cancer[J]. Current Opinion in Cell Biology, 2004, (06): 623-628.

[23] Kenny K K Chung, Zhang Yi, Kah Leong Lim, et al. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1:implications for Lewy-body formation in Parkinson disease[J]. Nat Med, 2001, 7(10): 1144-1150.

[24] Yuzuru Imai, Mariko Soda, Haruhisa Inoue, et al. An unfolded putative transmembrane polypeptide, which canlead to endoplasmic reticulum stress, is a substrate of Parkin[J]. Cell, 2001, 105(7): 891-902.

[25] Lechtenberg B C, Rajput A, Sanishvili R, et al. Structure of a HOIP/E2~ubiquitin complex reveals RBR E3 ligase mechanism and regulation[J]. Nature, 2016, 529(7587): 546-550.

[26] Edgar R Kramer. The neuroprotective and regenerative potential of parkin and GDNF/Ret signaling in the midbrain dopaminergic system[J]. Neural Regen Res, 2015, 10(11): 1752-1753.

[27] Duong P Huynh, Daniel R Scoles, Dung Nguyen, et al. The autosomalrecessive juvenile Parkinson disease gene product, Parkin, interactswith and ubiquitinates synaptotagmin XI[J]. Hum Mol Genet, 2003, 12(20): 2587-2597.

[28] Glass A S, Huynh D P, Franck T, et al. Screening formutations in synaptotagmin XI in Parkinson's disease[J]. Neural Transm, 2004, Suppl(68): 21-28.

[29] Romina Romaniello, Filippo Arrigoni, Maria Teresa Bassi, et al. Mutations in α-and β-Tubulin encoding genes: impplications in the brain malformations[J]. Brain Dev, 2015, 37(3): 273-280.

[30] Satropoli J F, McDermott C, Martinat C, et al. Parkin is a component of an SCF-like ubiqution ligase complex and proteceta postmitotic neurons from kainate excitotoxicity[J]. Neuron, 2003, 37(5): 735-749.

[31] 袁瑾静, 夏韵. 复方蒲黄汤对缺血性脑损伤小鼠脑组织中Parkin、Cyclin E蛋白的影响[J]. 同济大学学报: 医学版, 2014, 35(5): 38-46.

[32] Kyoko Ikeuchi, Hiroyuki Marusawa, Mikio Fujiwara, et al. Attenuation of proteolysis-mediated cyclin E regulation by alternatively spliced Parkin in human colorectal cancers[J]. Tnternational J Cancer, 2009, 125(9): 2029-2035.

[33] Emanuel Ferreira-Femandes, Sara L C Esteves, Luís Korrodi-Gregório, et al. Synphilin-1A is a Phosphoprotein Phosphatase 1-Interacting Protein and Affects PPP1 Sorting to Subcellular Compartments[J]. J Molecular Neuroscience, 2015, 55(2): 385-395.

[34] Li Xue-ping, Yada Treesukosol, Alexander Moghadam, et al. Behavioral characterization of the hyperphagia synphilin-1 overexpressing mice[J]. PLoS One, 2014, 9(5): e91449/1-e91449/8, 8pp.

[35] Casadei Nicolas, Poehler Anne-Maria, Tomas-Zapico Cristina, et al. Overexpression of synphilin-1 promotes clearance of soluble and misfolded alpha-synuclein without restoring the motor phenotype in aged A30P transgenic mice[J]. Human Molecular Genetics, 2014, 23(3): 787-781.

[36] Okui Michiyo, Yamaki Akiko, Takayanagi Atsushi, et al. Transcription factor single-minded 2 (SIM2) is ubiquitinated by the RING-IBR-RING-type E3 ubiquitin ligases[J]. Experimental Cell Research, 2005, 309(1): 220-228.

[37] Zhao Jing-hui, Ren Yong, Jiang Qian, et al. Parkin is recruited to the centrosome in response to inhibition of proteasomes[J]. Cell Sc, 2003, 116(Pt 19): 4011-4019.

[38] James A Olzmann, Lih-Shen Chin. Parkin-mediated K63-linked polyubiquitination: a signal for targeting misfolded proteins to the aggresome-autophagy pathway[J]. Autophagy, 2008, 4(1): 85-87.

[39] Kao shyan-Yuan. Regulation of DNA repair by Parkin[J]. Biochemical Biophysical Reaserch Communications, 2009, 382(2): 321-325.

[40] Qu Dian-bo, Ali Hage, Katie Don-Carolis, et al. BAG2 gene-mediated regulation of PINK1 protein is critical for mitochondrial translocation of PARKIN and neuronal survival[J]. J Biol Chem, 2015, 290(51): 30441-30452.

[41] Yuzuru Imai, Mariko Soda, Shigetsugu Hatakeyama, et al. CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity[J]. Molecular Cell, 2002, 10(1): 55-67.

[42] Sangrem S Parelkar, Juan G Cadena, Chul Kim, et al. The Parkin-like human homolog of drosophila ariadne-1 (HHARI) can induce aggresome formation in mammalian cells and is immunologically detectable in lewy bodies[J]. J Molecular Neuroscience, 2012, 46(1): 109-121.

[43] Fatima Elmehdawi, Wheway Gabrielle, Szymanska Katarzyna, et al. Human homolog of drosophila ariadne (HHARI) is a marker of cellular proliferation associated with nuclear bodies[J]. Experimental Cell Research, 2013, 319(6): 161-172.

[44] Sun M, Latou relle J C, Woten G F, et al. Influence of heterozygosity for Parkin mutation on onsetage in familial Parkinson disease: the Gene PD study[J]. Arch Neurol, 2006, 63: 826 -832.

[45] Konovalova E V, Lopacheva O M, Grivennikov I A, et al. Mutations in the Parkinson's disease-associated PARK2 gene are accompanied by imbalance in programmed cell death systems[J]. Acta Naturae, 2015,7(4): 146-149.

[46] 李立宏, 高国栋. 帕金森病基因突变多态性与其家族性和散发性的关系[J]. 中国临床康复, 2005, 9(17): 13-15.

[47] Marder K S, Tang M X, Mejia-Santana H, et al. Predictors of Parkin mutation sinearly -onset Parkinson disease: theconsortium on risk for early-onset Parkinson disease study[J]. Arch Neurol, 2010, 67 (6): 731-738.

[48] Konovalova E V, Lopacheva O M, Igor A Grivennikov, et al. Mutations in the Parkinson's disease-associated PARK2 gene are accompanied by imbalance in programmed cell death systems[J]. Acta Naturae, 2015, 7(4): 146-149.

[49] 聂利珞, 郭纪锋, 张海南, 等. 中国南方汉族散发早发性帕金森综合征的Parkin 基因突变分析[J]. 中华神经科杂志, 2010, 43(10): 692-696.

[50] 刘珂, 滕继军, 王修海. 散发性帕金森病 Parkin基因突变检测[J]. 青岛大学医学院学报, 2009, 45(2): 104-106.

[51] Esther S P Wong, Jeanne M M Tan, Wang Cheng, et al. Relative sensitivity of Parkin and other cysteine-containing enzymes to stress-induced solubility alterations[J]. Biol Chem, 2007, 282(16): 12310-12318.

[52] Schlehe J S, Lutz A K, Pilsl A, et al. Aberrant folding of pathogenic Parkin mutants: aggregation versus degradation[J]. J Biol Chem, 2008, 283(20): 13771-13779.

[53] Linda Narhi, Stephen J Wood, Shirley Steavenson, et al. Both familial Parkinson’s disease mutation accelerate alpha-Syn aggregation [J]. J Biol Chem, 1999, 274(14): 9843-9846.

[54] Toru Yasuda, Hideki Mochizuki. The regulatory role of a-synuclein and Parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson’s disease[J]. Apoptosis, 2010, 15(11): 1312-1321.

[55] Lonskaya Irina, Desforges Nicole M, Hebron Michaeline L, et al. Ubiquitination increases Parkin activity to promote autophagic α-synuclein clearance[J]. PLoS One, 2013, 8(12): e83914/1-e83914/12, 12 pp.

[56] Preeti J Khandelwal, Sonya B Dumanis, Li Rebekah Feng, et al. Parkinson-related Parkin reduces α-Synuclein phosphorylation in a gene transfer model[J], Molecular Neruodegeneration, 2010, 5: 47.

[57] Fournier Margot, Roux Amandine, Garrigue Jerome, et al. Parkin depletion delays motor decline dose-dependently without overtly affecting neuropathology in α-synuclein transgenic mice[J]. BMC Neuroscience, 2013, 14: 135/1-135/13, 13 pp.

[58] 柏杖勇, 李清华. PINK1/Parkin, 线粒体自噬与帕金森病[J]. 中国老年学杂志, 2014, 5(34): 2609-2613.

[59] Fumika Koyano, Kei Okatsu, Hidetaka Kosako, et al. Ubiquitin is phosphorylated by PINK1 to activate Parkin[J]. Nature, 2014, 510(7503): 162-166.

[60] Jessica A Williams, Ding Wen-xing. Targeting Pink1-Parkin-mediated mitophagy for treating liver injury[J]. Pharmacol Res, 2015, 102: 264-269.

[61] Pei-I Tsai, Meredith M Course, Jonathan R Lovas, et al. PINK1-mediated phosphorylation of miro inhibits synaptic growth and protects dopaminergic neurons in drosophila[J], 2014, 4: 6962.

[62] Wang X, Zhao X L, Xu L L, et al. Mitophagy in APPsw/PS1dE9 transgenic mice and APPsw stably expressing in HEK293 cells[J]. Eur Rev Med Pharmacol Sci, 2015, 19(23): 4595-602.

[63] 贾焕珍, 鲁玲, 龚普盛, 等. PINK1 参与调节多巴胺的合成[J]. 基础医学与临床, 2012, 32(1): 16-20.

[64] 王雪晶, 郭纪锋, 江泓, 等. 帕金森病相关蛋白Parkin与PINK1的相互作用研究[J]. 生物化学与生物物理进展, 2010, 37(9): :983-987.

[65] Tan Eng-King. PINK1- and DJ-1-linked parkinsonism[J]. Parkinson's Disease: 2nd Edition, 2013: 175-180.

[66] Jennifer N Cremer, Katrin Amunts, Axel Schleicher, et al. Changes in the expression of neurotransmitter receptors in Parkin and DJ-1 knockout mice-A quantitative multireceptor study[J]. Neuroscience, 2015, 311: 539-551.

[67] Aleyasin H, Rousseaux M W, Marcogliese P C, et al. DJ-1 protects the nigrostriata l axis from the neurotoxin MPTP by modulation of the AKT pathway[J]. Proc Natl Acad Sci USA, 2010, 107(7): 3186-3191.

[68] Eric Duplan, Emilie Giaime, Julien Viotti. ER-stress-associated functional link between Parkin and DJ-1 via a transcriptional cascade involving the tumor suppressor p53 and the spliced X-box binding protein XBP-1[J]. J Cell Science, 2013, 126(9): 2124-2133.

[69] Jean-Charles Paterna, Andreas Leng, Elisabeth Weber, et al. DJ-1 and parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice[J]. Mol Ther, 2007, 15(4): 698-674.

[70] Zhou M, Xia Z Y, Lei S Q, et al. Role of mitophagy regulated by Parkin/DJ-1 in remote ischemic postconditioning-induced mitigation of focal cerebral ischemia-reperfusion[J]. Eur Rev Med Pharmacol Sci, 2015, 19(24): 4866-4871.

[71] Meghan R Hennis, Katherine W Seamans, Marian A Marvin, et al. Behavioral and neurotransmitter abnormalities in mice deficient for Parkin, DJ-1 and superoxide dismutase[J]. PLoS One, 2013, 8(12): e84894/1-e84894/17, 17 pp.

[72] Sorin Breit, Wachter T, D Schmid Bielenberg, et al. Efective long-term subthalamic stimulation in PARK8 positive Parkinson’s disease[J]. J Neurology, 2010, 257(7): 1205- 1207.

[73] Tatsunori Maekawa, Makoto Kubo, Ikue Yokoyam, et al. Age-dependent and cell-population-restricted LRRK2 expression in nor-malmuse spleen [J]. Biochem Biophys Res Commun, 2010, 392(3): 431-435.

[74] 杜青青, 沈勤. LRRK2基因突变与帕金森病[J]. 江苏大学学报: 医学版, 2010, 20(5): 455-458.

[75] Lin Xian, Loukia Parisiadou, Gu Xing-long, et al. Leucine rich repeatkinase regulates the progression of neuro pathology induced by Parkinsons-disense related mutant alpha-synuclein [J]. Neuron, 2009, 64(6): 807-827.

[76] Huang Yue, Song Yun Ju Christine, Murphy Karen, et al. LRRK2 and Parkin immunoreactivity in multiple system atrophy inclusions[J]. Acta Neuropathologica, 2008, 116(6): 639-646.

[77] Ng Chee-Hoe, Guan Melissa S H, Koh Cherlyn, et al. AMP kinase activation mitigates dopaminergic dysfunction and mitochondrial abnormalities in Drosophila models of Parkinson's disease[J]. J Neuroscience, 2012, 32(41): 14311-14317.

[78] Ng Chee-Hoe, Shaun Z S Mok, Cherlyn Koh, et al. Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila[J]. J Neuroscience, 2009, 29(36): 11257-11262.

[79] Nadia Iovieno, Andres A Nierenberg, Susannah R Parkin, et al. Relationship between placebo response rate and clinical trial outcome in bipolar depression[J]. J Psychiatr Res, 2015, 74: 38-44.

[80] 杨智明, 李煦照, 卢芳, 等. 帕金森病的线粒体发病机制研究进展[J]. 中国老年学杂志, 2014, (21): 6233-6235.

[81] Dmitry B Zorov, Magdalena Juhaszova, Steven J Sollott. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release[J]. Physiol Rev, 2014, 94(3): 909-950.

[82] Ghazaleh Ashrafi, Julia S Schlehe, Matthew J LaVoie, et al. Mitophagy of damaged mitochondria occurs locally in distal neuronal axons and requires PINK1 and Parkin[J]. J Cell Biology, 2014, 206(5): 655-670.

[83] 李玉娟, 王丹巧. 线粒体功能障碍与帕金森病关系研究进展[J]. 中国药理学和毒理学杂志, 2013, 27(4): 727-730.

[84] 曾爱源, 李琼, 黄强, 等. 过表达PINK1改善SCA3/MJD转基因果蝇模型的线粒体功能[J]. 中国生物化学与分子生物学报, 2015, 31(1): 88-95.

[85] Derek P Narendra, Richard J Youle. Targeting mitochondrial dysfunction role for PINK1 and Parkin in mitochondrial quality control[J]. Antioxid Redox Signal, 2011, 14(10): 1929-1938.

[86] Van Humbeeck Cindy, Cornelissen Tom, Hofkens Hilde, et al. Parkin interacts with Ambral to induce mitophagy[J]. J Neurosci, 2011, 7(11): 1555-1556.

[87] Di Sha, Lih-Shen Chin, Lian Li. Phosphorylation of Parkin by Parkinson disease-linked kinase PINK1 activates Parkin E3 ligase function and NF-κB signaling[J]. Hum Mol Genet, 2010, 19(2): 352-363.

[88] Richard J Youle, Derek P Narendra. Mechanisms of mitophagy[J]. Nat Rev Mol Cell Biol, 2011, 12(1): 9-14.

[89] Marques-Aleixo I, Santos-Alves E, Balça MM, et al. Physical exercise mitigates doxorubicin-induced brain cortex and cerebellum mitochondrial alterations and cellular quality control signaling[J]. Mitochondrion, 2015, 26: 43-57.

Advances in Parkinson’s Disease-Causing Gene Parkin

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

[1]	XIE bin, HUANG Zhi-yuan, LIN Duo-duo, YANG Fu-long, XIE Yi-bin.Effect of Acupuncture Combined with Medicine on Depressive Symptoms of Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 5-8.
[2]	SUN Li-cong, ZHANG Dan-shen.Research Progress on Potential Treatment of Alzheimer’s Disease with Alkaloids[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 33-37.
[3]	WANG Si-yi, LI Xian-xiang, LIU Yi-zhou, DU Shuang, GE Chao, LIU Si-si.Current Situation and Prospect of Alzeimer’s Disease Treatment[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 38-42.
[4]	ZHAO Yu-wei, ZHEN Yan-jie, DAI Yue-ying, SHEN Li-xia.Study on the Neuroprotective Mechanism of Quercetin in Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 55-64.
[5]	HAI Ji-tao, LUO Huan-min.Progress on the Relationship between Pathogenic Microorganisms and Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(4): 58-64.
[6]	ZHANG Hao-ting, SONG Gui-qin, CUI Ruo-tong, HAO Min, WANG Wen-dong.Mining Target Genes of Alzheimer’s Disease Associated with Biological Clock by Bioinformatics Analysis[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(3): 1-7.
[7]	YANG Xu-hua, DU Shuang, SHEN Li-xia, HAO Jun-rong.Research Progress in Drug Treatment of Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(3): 47-53.
[8]	ZHEN Yan-jie, GUO Tong-lin, ZHAO Yu-wei, SHEN Li-xia.Study Progress on Phytoestrogen-Mediated Mitochondrial Pathway’s Neuroprotective Effects in Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(1): 40-46.
[9]	YANG-Lin，AI-Jing.Research Progress of Brain-Derived Estrogen in Alzheimer’s Disease[J]. Acta Neuropharmacologica, 2019, 9(5): 50-64.
[10]	ZHANG Shuai，AI Jing.Glutamate Dysfunction and Alzheimer’s Disease[J]. Acta Neuropharmacologica, 2018, 8(6): 9-20.
[11]	王奇.Bushen-Yizhi Formula Inhibits the NLRP3/NFκB Mediated Neuroinflammation and Improves the Motor Dysfunction in a Mouse Model of Parkinson's Disease[J]. Acta Neuropharmacologica, 2018, 8(5): 71-72.
[12]	CUI Su-ying, SONG Jin-zhi, CUI Xiang-yu, HU Xiao, DING Hui, YE Hui, ZHANG Yong-he.Intracerebroventricular Streptozocin-induced Alzheimer’s Disease-like Sleep Disorders: Role of the GABAergic System in the Parabrachial Complex[J]. Acta Neuropharmacologica, 2018, 8(5): 96-97.
[13]	YU Li-li1，2，XU Li1，WANG Yi-nuo1，XUE Lu-ning1，Gou Ji-wei1，LI Hong-bo1，HOU Xue-qin1，ZHANG Han-ting1.Effects of Osthole on Learning and Memory and the Estrogen Pathway in Ovariectomized Rats[J]. Acta Neuropharmacologica, 2018, 8(4): 7-8.
[14]	SHEN li-xia1，LIU Liang-liang1，ZHANG Ming1，LIU Yang1，ZHANG Dan-shen 2*.Research of Quercetin’s Estrogen-Like Action on Central Nervous System and Its Mechanisms[J]. Acta Neuropharmacologica, 2018, 8(4): 23-25.
[15]	WANG Hao1, ZHANG Fang-fang1, FU Hua-rong1, ZHOU Yan-meng1, LIU Xin1, HOU Xue-qin 1, HU Wei2, Rolf Hansen2, XU Ying3, James O’Donnell3, ZHANG Han-ting1,2.Targeting PDE4 for Alzheimer’s Disease and Alcoholism: An implication in Alcohol-Related Dementia?[J]. Acta Neuropharmacologica, 2018, 8(4): 39-41.